Vertex has gained the FDA's approval for its nonaddictive pain med Journavx, which becomes the first significant innovation ...

The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or ...

The Massachusetts-based biotech plans to use the funds to push its candidates into mid-stage clinical trials in a space ...

A new EMA approval has expanded the use of Vertex ... in the US (as Trikafta) and was approved by the European Commission in August. Kaftrio covers a broader set of CFTR mutations spanning 90% ...

Vertex received FDA approval for the expanded use of TRIKAFTA in patients with 94 additional non-F508del CFTR mutations. With this approval, approximately 300 people in the U.S. are newly eligible ...

In Q3, Vertex generated $1.369 billion from operating activities. Given Trikafta's powerful revenue generation and a solid balance sheet, Vertex's financial health is well and supports their ...

FDA approval of ALYFTREK and TRIKAFTA expands CF treatment options to over 300 mutations, benefiting 300 ... Earnings Report RBC Capital Markets says Vertex management is optimistic about the ...

This can be attributed to: Vertex Pharmaceuticals’ revenue growth has been driven by strong uptake in Trikafta/Kaftrio – a prescription medicine used for the treatment of cystic fibrosis ...

AbbVie, Vertex Pharmaceuticals, and Thermo Fisher Scientific are the three Biotech stocks to watch today, according to ...

Shares of Vertex Pharmaceuticals (NASDAQ ... caused by at least one of 303 possible mutations in their CFTR genes. Alyftrek's precursor, Trikafta, earned approval to treat cystic fibrosis patients ...

TRIKAFTA: Also on December 20, 2024, Vertex received FDA approval for the expanded use of TRIKAFTA in patients with 94 additional non-F508del CFTR mutations. With this approval, approximately 300 ...